Wolters Kluwer announces institutional availability of NEJM AI on Ovid

2024-02-01
Wolters Kluwer announces institutional availability of NEJM AI on Ovid
Preview
来源: Business Wire
'With the proliferation of generative AI (GenAI) applications across industries, it\u2019s clear that AI will have a profound impact on healthcare. Wolters Kluwer is at the forefront of bringing together expert solutions with trusted and authoritative research information'
Wolters Kluwer announces institutional availability of NEJM AI on Ovid
Preview
来源: Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Wolters Kluwer Health and NEJM Group, publishers of the New England Journal of Medicine (NEJM), announced today that the new NEJM AI journal is now available on Wolters Kluwer’s Ovid® medical research platform.
NEJM AI is a peer-reviewed monthly journal dedicated to exploring and integrating artificial intelligence (AI) in clinical medicine. Hospitals, government agencies, corporations, health systems and research institutions are able to access the journal organization wide through Ovid’s exclusive digital distribution of NEJM Group titles. Institutional access to NEJM AI builds upon a collaboration that enables online subscriptions to NEJM Group journals such as New England Journal of Medicine, NEJM Evidence, NEJM Catalyst and NEJM Journal Watch, where users can access subscriber content both on NEJM Group sites and on Ovid.
Bridging trusted research with the future of health
“With the proliferation of generative AI (GenAI) applications across industries, it’s clear that AI will have a profound impact on healthcare. Wolters Kluwer is at the forefront of bringing together expert solutions with trusted and authoritative research information,” said Rafael Sidi, Senior Vice President & General Manager of Health Research, Wolters Kluwer Health. “The medical field is at a pivotal juncture, with technology rapidly revolutionizing patient care to improve outcomes significantly. NEJM AI serves as a critical resource for clinicians, researchers, healthcare leaders, and policymakers globally, focusing on the transformative role of AI and machine learning.”
NEJM Group launched NEJM AI as a groundbreaking journal to advance the understanding and practical application of AI in medicine. The journal aims to link cutting-edge AI technology and practical medical applications that can one day transform patient care and healthcare outcomes. Led by renowned experts in medical AI, the global editorial leadership of NEJM AI brings together the best minds in medical AI research from various disciplines.
“NEJM AI will apply the same rigorous standards as our flagship journal to determine which AI tools are ready for use in medical settings,” said Isaac Kohane, M.D., Ph.D., Editor-in-Chief of NEJM AI. “We are not only publishing high-quality original research but aim to build a community of engagement that fosters open conversation among AI developers, clinicians, researchers, healthcare leaders and government officials.”
In addition to the new journal, NEJM Group offers “NEJM AI Grand Rounds,” a podcast that explores the deep issues at the intersection of artificial intelligence, machine learning, and medicine. The podcast will be complemented by community-building activities such as events and exclusive subscriber content looking at the forefront of marrying technological innovation with clinical expertise.
The Ovid research platform provides a vast library of thousands of full-text journal articles, eBooks, database resources, and workflow tools in a single, integrated solution. Wolters Kluwer products, services, and expert solutions are based on a foundation of trust, transparency, and responsibility – in line with the company’s values. Wolters Kluwer’s AI Principles, which guide the design, development and deployment of advanced technologies in helping customers solve their most complex problems, can be found here.
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software, and services for professionals in healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, and YouTube.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。